TYK Medicines (HKG: 2410) announced that its independently developed new drug, asandeutertinib (TY‑9591), is set to complete production, with the first batch expected to be officially shipped via commercial channels by the end of November 2026 to Tier‑1 distributors designated by Qilu Pharmaceutical. Qilu is scheduled to launch academic promotion activities on 13 November 2026, marking the official commencement of commercial sales and prescription availability for asandeutertinib in China.
Commercial Launch Snapshot
| Item | Detail |
|---|---|
| Company | TYK Medicines (HKG: 2410) |
| Product | Asandeutertinib (TY‑9591) – independently developed new drug |
| Production Status | Set to complete production; first batch ready |
| First Shipment | By end of November 2026, via commercial channels to Tier‑1 distributors designated by Qilu Pharmaceutical |
| Academic Promotion Launch | 13 November 2026 (by Qilu Pharmaceutical) |
| Commercialization Partner | Qilu Pharmaceutical – commercialization in mainland China |
| Milestone | Official commencement of commercial sales and prescription availability in China |
| Pricing / Sales Targets | Not disclosed |
Regulatory Status – NMPA Conditional Approval
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA, China) |
| Approval Type | Conditional marketing approval |
| Approval Date | August 2026 |
| Indication | First‑line treatment of adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions (19DEL) or exon 21 (L858R) substitution mutations, accompanied by CNS metastases |
Drug Profile & Mechanism of Action
- Molecule: Asandeutertinib (TY‑9591) – a highly selective, irreversible EGFR tyrosine kinase inhibitor (EGFR‑TKI), independently developed by TYK Medicines.
- Differentiation: Has demonstrated superior efficacy and best‑in‑class potential across multiple clinical studies, particularly in two hard‑to‑treat subpopulations: patients with EGFR‑mutated NSCLC with brain metastases and those harboring the EGFR L858R mutation.
- CNS Activity: The NMPA label’s explicit inclusion of patients accompanied by CNS metastases underscores the drug’s blood‑brain‑barrier penetration – a key competitive axis in the EGFR‑TKI class, where brain metastases carry poor prognosis and limited treatment options.
- L858R Niche: Exon 21 L858R tumors historically respond less robustly to earlier‑generation TKIs; demonstrated best‑in‑class potential in this subgroup gives asandeutertinib a differentiated positioning claim.
- Selectivity: As a highly selective, irreversible inhibitor, the profile is designed to maximize on‑target EGFR blockade while limiting off‑target toxicities common to earlier generations.
Commercialization Pathway
- Channel Structure: First‑batch product flows to Tier‑1 distributors designated by Qilu Pharmaceutical, leveraging Qilu’s established nationwide oncology distribution and hospital‑access network.
- Launch Sequence: Academic promotion begins 13 November 2026, ahead of the end‑November shipment – seeding physician education and KOL engagement so prescription availability coincides with physical supply.
- Manufacturing Readiness: Completion of production for the first commercial batch converts the August 2026 regulatory win into tangible revenue potential for TYK’s first marketed product.
- Partnership Economics: Under the July 2026 TYK–Qilu agreement, Qilu holds rights to develop and produce TY‑9591 API and commercialize the drug in mainland China, with an RMB 300 million upfront and up to RMB 2.06 billion in milestones upon regulatory approvals and indication expansions – commercial launch marks the start of milestone‑eligible execution.
Market Impact & Outlook
- EGFR‑TKI Landscape: First‑line EGFR‑mutant NSCLC in China is a fiercely contested, multi‑billion‑RMB market (osimertinib, furmonertinib, aumolertinib among incumbents); asandeutertinib enters with a CNS‑metastases‑specific approved label and best‑in‑class claims in L858R – a defensible initial niche.
- TYK Inflection Point: The transition from R&D‑stage biotech to commercial‑stage company marks TYK’s first product revenue stream, with launch execution now the central equity story.
- Conditional Approval Obligations: As a conditional approval, confirmatory data obligations apply; continued trial completion will be watched alongside sales ramp.
- Key Catalysts Ahead: First‑batch shipment completion by end‑November 2026, uptake following academic promotion, provincial procurement/hospital listing progress, potential indication expansions triggering Qilu milestone payments, and full approval conversion – pricing and sales guidance not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding asandeutertinib (TY‑9591), including completion of production, first‑batch shipment timing, commencement of commercial sales, and market uptake in China. Actual results may differ due to risks including manufacturing and distribution execution, prescriber adoption, competitive dynamics in the EGFR‑TKI class, conditional approval confirmatory requirements, and reimbursement outcomes. Pricing and sales targets have not been disclosed.-Fineline Info & Tech
